Cureus, Год журнала: 2024, Номер unknown

Опубликована: Сен. 3, 2024

Introduction Virologic failure due to antiretroviral drug resistance is a threat efforts control the human immunodeficiency virus (HIV) epidemic. Understanding factors that influence genetic and clinical expression of fundamental for infection control. Methods A nested case-control study was conducted on cohort adult HIV patients between 2016 2022. The cases were defined as with confirmed diagnosis virologic resistance, indicated by viral genotype result. group consisted who had not experienced or undergone any documented changes their treatment. incidence over period calculated. characteristics each in frequency tables measures central tendency. To identify risk factors, multiple logistic regression models employed, post hoc tests conducted. All calculations performed 95% confidence intervals, p-values less than 0.05 considered significant. Results seven-year 9.2% (95% CI: 7.5-11.2%). Low CD4 T-lymphocyte count (≤200 cells/mm³) at (adjOR 14.2, 3.1-64.5), history opportunistic infections 3.5, 1.9-6.4), late enrollment into an program after (>1 year) 9.2, 3.8-22.2) identified independent predictors failure. drugs highest rates nevirapine (84.6%), efavirenz (82.4%), emtricitabine (81.3%), lamivudine atazanavir (6.6%). most prevalent major mutations K103N, M184V, M46I/M. Approximately 50% secondary protease regions. Conclusions low population. allow prediction profile susceptible early optimization treatment regimens.

Язык: Английский